DBV Technologies (DBVT) Other Accumulated Expenses (2019 - 2026)
DBV Technologies (DBVT) posted Other Accumulated Expenses of $13.8 million for Q2 2026, up 27.78% sequentially from $10.8 million in Q1 2026, and up 83.56% YoY from $7.5 million in Q2 2025.
Analysis
DBV Technologies (DBVT) Other Accumulated Expenses (2019 - 2026) Analysis & Trends
DBV Technologies has reported Other Accumulated Expenses for 8 years, with the latest figure at $13.8 million in Q2 2026.
- Quarterly Other Accumulated Expenses rose 83.56% year-over-year to $13.8 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $13.8 million (up 83.56% YoY) and the FY2025 annual result came in at $15.8 million, up 89.72% from the prior year.
- Other Accumulated Expenses advanced to $13.8 million in Q2 2026 per DBVT's latest filing, from $10.8 million in the prior quarter.
- Over five years, Other Accumulated Expenses peaked at $15.8 million in Q4 2025 and troughed at $5.0 million in Q1 2024.
- A 5-year average of $8.7 million and a median of $8.5 million in 2022 frame the typical range for Other Accumulated Expenses.
- The sharpest annual moves came in 2022 and 2026: Other Accumulated Expenses sank 34.9% in 2022, then soared 98.27% in 2026.
- Over 5 years, Other Accumulated Expenses stood at $9.2 million in 2022, then slipped by 3.0% to $8.9 million in 2023, then slipped by 6.78% to $8.3 million in 2024, then surged by 89.72% to $15.8 million in 2025, then decreased by 12.66% to $13.8 million in 2026.
- According to Business Quant data, Other Accumulated Expenses over the past three periods registered $13.8 million, $10.8 million, and $15.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn |
| 10 | DBV Technologies | 5.88 Bn | 5.71 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 13.80 Mn |
| Mar 31, 2026 | 10.80 Mn |
| Dec 31, 2025 | 15.80 Mn |
| Sep 30, 2025 | 8.45 Mn |
| Jun 30, 2025 | 7.52 Mn |
| Mar 31, 2025 | 5.45 Mn |
| Dec 31, 2024 | 8.33 Mn |
| Sep 30, 2024 | 7.79 Mn |
| Jun 30, 2024 | 6.16 Mn |
| Mar 31, 2024 | 5.02 Mn |
| Dec 31, 2023 | 8.93 Mn |
| Sep 30, 2023 | 8.67 Mn |
| Jun 30, 2023 | 7.26 Mn |
| Mar 31, 2023 | 6.78 Mn |
| Dec 31, 2022 | 9.21 Mn |
| Sep 30, 2022 | 8.62 Mn |
| Jun 30, 2022 | 8.78 Mn |
| Mar 31, 2022 | 8.72 Mn |
| Dec 31, 2021 | 12.36 Mn |
| Sep 30, 2021 | 12.66 Mn |